GeneDx Holdings Corp (WGS) reports robust revenue growth and unveils new products, despite facing reimbursement challenges.
GeneDx stock catapulted Tuesday after the top-notch biotech smashed fourth-quarter expectations and issued upbeat guidance.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...
President and CEO Katherine Stueland stated that GeneDx achieved significant milestones in 2024, including surpassing $95 million in Q4 revenue and expanding gross margins to 70%. She highlighted the ...
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...
While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...
Market OverviewThe Global Carrier Screening Market is a genetic testing process that determines whether an individual carries ...
Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...
Western genomes won’t cut it. Experts from IIT Madras and Karkinos Healthcare, leading the Bharat Cancer Genome Atlas (BCGA), ...
A groundbreaking study reveals how a rare combination of genetics, proteomics, and environmental factors may hold the key to ...